Preliminary data show that one of the six lines of induced pluripotent stem cells being studied by BioTime had enough of the protein telomerase to reverse cellular aging, making the iPS cell line a potential alternative to embryonic stem cells. BioTime CEO Michael West expressed optimism that the company is "years away -- not decades away -- from clinical trials."

Related Summaries